Advertisement

Selective upregulation of MHC class I expression in metastatic colonies derived from tumor clones of a murine fibrosarcoma

  • S. Pedrinaci
  • A. Garcia Lora
  • M. Perez
  • F. Garrido
  • I. Algarra
  • J. J. Gaforio
  • F. Garrido
Original

Abstract

Eighteen metastatic nodes derived from the wild-type (GR9) and from 4 different clones (G2, D8, B10, and B9) obtained from a fibrosarcoma were analyzed for H-2 class I and II expression, as well as for adhesion molecules (CD44, CDllb, CD18, CD49, and CD54). When metastatic nodes were cultured, typed for H-2 antigens, and compared with the H-2 expression of the inducing tumor cell, H-2 Kd and Dd class I expression was greater in most nodes analyzed. In contrast, the Ld molecule remained negative, or showed a minor increase. Class II expression was negative in the wild-type and the tumor clones, and remained so in the metastatic colonies. Analysis of the adhesion molecules revealed no differences between the inducing tumor cells and the metastatic nodes. The only molecule expressed was CD44, which was present in all cells studied and was also inducible by interferon-γ. The increase in H-2K and H-2D expression was associated with resistance to natural killer cytotoxicity, as observed in the G2 tumor clone and some autologous metastases, such as B9MP2, G2MK2, and G2ML1. In three independent clones of this tumor system (D8, B10MP6, and B9MP6) we found that tumor cells treated with interferon-γ had the same altered phenotype, i.e., a selective lack of response of the Ld molecule to induction. These findings add a cautionary note to the well-established idea that tumor cells may lose all class I antigens during tumor progression, and suggest that sometimes this may not be the case. The selective downregulation of Ld and upregulation of Kd and Dd class I expression may give some tumor cells means of escaping both cytotoxic lymphocyte and natural killer immune surveillance.

Key words

MHC Metastasis Tumor cells Natural killer cells T cells 

References

  1. 1.
    Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern P L. Natural history of HLA expression during tumour development. Immunol Today 1993;14:491.PubMedCrossRefGoogle Scholar
  2. 2.
    Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells. Molecular mechanisms, functional significance and clinical relevance. Immunol Today 1994;87:284.Google Scholar
  3. 3.
    Cabrera T, Fernandez M, Sierra A, Garrido A, Herruzo A, Escobedo A, Fabra A, Garrido F. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 1996; 50:127.PubMedCrossRefGoogle Scholar
  4. 4.
    Cabrera T, Collado A, Fernandez M, Ferron A, Sancho J, Ruiz-Cabello F, Garrido F. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens 1998; 52:114.PubMedGoogle Scholar
  5. 5.
    Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18:89.PubMedCrossRefGoogle Scholar
  6. 6.
    Lopez Nevot M, Esteban F, Ferron A, Gutierrez J, Oliva MR, Romero C, Huelin C, Ruiz-Cabello F, Garrido F. HLA class I gene expression on human primary tumours and autologous metastasis: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 1989; 59:221.PubMedGoogle Scholar
  7. 7.
    Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995; 25:340.PubMedCrossRefGoogle Scholar
  8. 8.
    Cromme FV, Bomme LPF van, Walboomers JM, Gallee MP, Stern PL, Kenemans P, Hemerhost TJ, Stukart MJ, Meijer CJ. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 1994; 69:1176.PubMedGoogle Scholar
  9. 9.
    Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Harris AL. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res 1995; 55:5191.PubMedGoogle Scholar
  10. 10.
    Ikeda H, Lethe B, Lehmann F, Van Baren N, Baurain JF, De Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie P. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997; 6:199.PubMedCrossRefGoogle Scholar
  11. 11.
    Perez M, Garrido A, Algarra I, Garrido F. Different H-2 phenotypes in clones derived from a new BALB/c solid tumor. Its relevance for local tumor growth. Immunologia 1985; 4:60.Google Scholar
  12. 12.
    Garrido A, Perez M, Delgado C, Garrido ML, Rojano J, Algarra I, Garrido F. The influence of class I H-2 gene expression on local tumor growth. Description of a model obtained from clones derived from a solid BALB/c tumor. Exp Clin Immunogenet 1986; 3:98.PubMedGoogle Scholar
  13. 13.
    Algarra I, Gaforio JJ, Garrido A, Mialdea MJ, Perez M, Garrido F. Heterogeneity of MHC class I antigens in clones of methylcholantrene induced tumors. Implications for local growth and metastasis. Int J Cancer 1991; 6 [Suppl]:73.CrossRefGoogle Scholar
  14. 14.
    Algarra I, Öhlen C, Perez M, Ljunggren HG, Klein G, Garrido F, Karre K. NK sensitivity and lung clearance of MHC-Class I-deficient cells within a heterogeneous fibrosarcoma. Int J Cancer 1989; 44:675.PubMedCrossRefGoogle Scholar
  15. 15.
    Perez M, Algarra I, Ljunggren HG, Caballero A, Mialdea MJ, Gaforio JJ, Klein G, Karre K, Garrido F. A weakly tumorigenic phenotype with high MHC class I expression is associated with high metastatic potential after surgical removal of the primary murine fibrosarcoma. Int J Cancer 1990; 46:258.PubMedCrossRefGoogle Scholar
  16. 16.
    Festenstein H. The biological consequences of altered MHC expression on tumors. Br Med Bull 1987; 43:217.PubMedGoogle Scholar
  17. 17.
    Eisenbach L, Hollander N, Greenfeld L, Yakor H, Segal S, Feldman M. The differential expression of H-2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. Int J Cancer 1984; 34:567.PubMedCrossRefGoogle Scholar
  18. 18.
    Ruiz-Cabello F, Klein E, Garrido F. MHC antigens in human tumors. Immunol Lett 1991; 29:181.PubMedCrossRefGoogle Scholar
  19. 19.
    Van Duinen SG, Ruiter DJ, Brocker EB. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988; 48:1019.PubMedGoogle Scholar
  20. 20.
    Wang Z, Margulies L, Hicklin DJ, Ferrone S. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression. Tissue Antigens 1996; 47:382.PubMedCrossRefGoogle Scholar
  21. 21.
    Browning M, Petronzelli F, Bicknell D, Krausa P, Rowan A, Tonks S, Murray N, Bodmer J, Bodmer W. Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens 1996; 47:364.PubMedGoogle Scholar
  22. 22.
    Torres MJ, Ruiz-Cabello F, Skoudy A, Berrozpe G, Jimenez P, Serrano A, Real AX, Garrido F. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens 1996; 47:372.PubMedGoogle Scholar
  23. 23.
    Zheng P, Guo Y, Niu Q, Lwvy DE, Dyck JA. Lu S, Sheiman LA. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 1998; 396:373.PubMedCrossRefGoogle Scholar
  24. 24.
    Cohen GB, Gandhi RT, Davis MD, Mandelboim O, Chen BK, Strominger JL, Baltimore D. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999; 6:661.CrossRefGoogle Scholar
  25. 25.
    Blom DJR, Luyten GPM, Mooy C, Kerkuliet S, Zwinderman AH, Jager MJ. Human leukocyte antigen class I expression. Invest Ophthamol Vis Sci 1997; 38:1865.Google Scholar

Copyright information

© Springer-Verlag 1999

Authors and Affiliations

  • S. Pedrinaci
    • 1
  • A. Garcia Lora
    • 1
  • M. Perez
    • 1
  • F. Garrido
    • 1
  • I. Algarra
    • 2
  • J. J. Gaforio
    • 2
  • F. Garrido
    • 3
  1. 1.Department Analisis Clinicos, Hospital Universitario Virgen NievesUniversidad De GranadaGranadaSpain
  2. 2.Department Ciencias De La Salud, Facultad De Ciencias ExperimentalesUniversidad De JaenJaenSpain
  3. 3.Department Analisis ClinicosHospital Universitario Virgen de las Nieves, AvdaGranadaSpain

Personalised recommendations